BALTIMORE--(BUSINESS WIRE)--Cerecor Inc. (NASDAQ: CERCU), a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the units issued in Cerecor's recent initial public offering will separate on November 13, 2015. Each unit consists of one share of common stock of Cerecor, one Class A warrant to purchase one additional share of common stock of Cerecor and one Class B warrant to purchase one-half additional share of common stock of Cerecor.
At the commencement of trading on November 13th, 2015, the common stock, the Class A warrants and the Class B warrants will trade separately on The NASDAQ Capital Market under the symbols "CERC", "CERCW" and "CERCZ", respectively. The units, which are currently traded under the symbol "CERCU", will no longer be listed on The NASDAQ Capital Market following the separation.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
About Cerecor
Cerecor Inc. is a Baltimore-based
biopharmaceutical company with the goal of becoming a leader in the
development of innovative drugs that make a difference in the lives of
patients with neurological and psychiatric diseases by addressing the
unmet medical needs of underserved patient segments. We are committed to
the development of drugs that improve lives by applying our extensive
knowledge and experience in central nervous system disorders.
www.cerecor.com
Forward-Looking Statements
This press release may include
forward-looking statements made pursuant to the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are statements
that are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Cerecor’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Cerecor’s plans, objectives,
projections, expectations and intentions and other statements identified
by words such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions. These statements are based upon the
current beliefs and expectations of Cerecor’s management but are subject
to significant risks and uncertainties, including those detailed in
Cerecor’s filings with the Securities and Exchange Commission. Actual
results (including, without limitation, the timing for the separation of
Cerecor’s publicly traded units into their component securities as
described herein) may differ from those set forth in the forward-looking
statements. Except as required by applicable law, Cerecor expressly
disclaims any obligations or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to
reflect any change in Cerecor’s expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.
